Literature DB >> 21162331

Angiotensin receptor blockers, cancer, and smoking.

Iñaki Marina1, Lawrence R Krakoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21162331      PMCID： PMC8673088          DOI： 10.1111/j.1751-7176.2010.00375.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  24 in total

Review 1.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

Authors:  Ilke Sipahi; Sara M Debanne; Douglas Y Rowland; Daniel I Simon; James C Fang
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

2.  Angiotensin-receptor blockers and cancer: urgent regulatory review needed.

Authors:  Steven E Nissen
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

3.  Calcium-channel blockade and incidence of cancer in aged populations.

Authors:  M Pahor; J M Guralnik; L Ferrucci; M C Corti; M E Salive; J R Cerhan; R B Wallace; R J Havlik
Journal:  Lancet       Date:  1996-08-24       Impact factor: 79.321

4.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Authors:  Frans H H Leenen; Chuke E Nwachuku; Henry R Black; William C Cushman; Barry R Davis; Lara M Simpson; Michael H Alderman; Steven A Atlas; Jan N Basile; Aloysius B Cuyjet; Richard Dart; James V Felicetta; Richard H Grimm; L Julian Haywood; Syed Z A Jafri; Michael A Proschan; Udho Thadani; Paul K Whelton; Jackson T Wright
Journal:  Hypertension       Date:  2006-07-24       Impact factor: 10.190

6.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Authors:  John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

7.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Authors:  Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

8.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

9.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-11-14       Impact factor: 17.586
View more
  1 in total

1.  Angiotensin and systems thinking: wrapping your mind around the big picture.

Authors:  Gary Robert Smith
Journal:  Ochsner J       Date:  2013
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.